BreastDefense answers a very simple but fundamental question. Is this tumor an indolent lesion, or an invasive breast cancer? This is a question that no other test can reliably answer. For breast cancer, the most common screening method - mammography - can be inaccurate. The New England Journal of Medicine estimates 31% of all breast cancer cases may be misdiagnosed.
BreastDefense does not rely on images, it is a lab developed molecular test.
Thousands of women are being misdiagnosed.
This needs to change.
With a simple blood draw, BreastDefense aims to distinguish benign and malignant tissue with a test that balances 98.5% accuracy for both sensitivity and specificity.
There is a clear path for commercializing BreastDefense
Step 1 The Validation Study Tissue Based – Timeline – 6-12 months.
Step 2 From the Validation Study a tissue-based test is ready for sale.
Step 3 Place BreastDefense in Blood Based Test (liquid biopsy) Timeline -12 months.
Step 4 BreastDefense Blood Based Screen is launched globally.